- Home
- EDSA
EDSA
Edesa Biotech Inc.
as of 03-19-2026 4:00pm EST
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
| Founded: | 2015 | Country: | Canada |
| Employees: | N/A | City: | MARKHAM |
| Market Cap: | 7.5M | IPO Year: | 2018 |
| Target Price: | $5.00 | AVG Volume (30 days): | 7.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.57 | EPS Growth: | -58.33 |
| 52 Week Low/High: | $0.72 - $8.74 | Next Earning Date: | 02-13-2026 |
| Revenue: | N/A | Revenue Growth: | -100.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -13.49 | Index: | N/A |
| Free Cash Flow: | -7322262.0 | FCF Growth: | N/A |
AI-Powered EDSA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Edesa Biotech Inc. (EDSA)
Chief Executive Officer
Avg Cost/Share
$6.60
Shares
1,000
Total Value
$6,598.90
Owned After
628,813
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$3.90
Shares
10,000
Total Value
$39,000.00
Owned After
628,813
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$4.26
Shares
10,000
Total Value
$42,560.00
Owned After
628,813
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$3.63
Shares
10,000
Total Value
$36,300.00
Owned After
628,813
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$2.14
Shares
3,000
Total Value
$6,279.60
Owned After
628,813
Chief Executive Officer
Avg Cost/Share
$2.22
Shares
30,000
Total Value
$66,696.00
Owned After
628,813
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$1.58
Shares
20,571
Total Value
$32,479.55
Owned After
628,813
SEC Form 4
President
Avg Cost/Share
$1.57
Shares
2,000
Total Value
$3,140.00
Owned After
226,870
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Nijhawan Pardeep | EDSA | Chief Executive Officer | Mar 10, 2026 | Buy | $6.60 | 1,000 | $6,598.90 | 628,813 | |
| Nijhawan Pardeep | EDSA | Chief Executive Officer | Mar 5, 2026 | Buy | $3.90 | 10,000 | $39,000.00 | 628,813 | |
| Nijhawan Pardeep | EDSA | Chief Executive Officer | Mar 4, 2026 | Buy | $4.26 | 10,000 | $42,560.00 | 628,813 | |
| Nijhawan Pardeep | EDSA | Chief Executive Officer | Mar 3, 2026 | Buy | $3.63 | 10,000 | $36,300.00 | 628,813 | |
| Nijhawan Pardeep | EDSA | Chief Executive Officer | Mar 2, 2026 | Buy | $2.14 | 3,000 | $6,279.60 | 628,813 | |
| Nijhawan Pardeep | EDSA | Chief Executive Officer | Feb 27, 2026 | Buy | $2.22 | 30,000 | $66,696.00 | 628,813 | |
| Nijhawan Pardeep | EDSA | Chief Executive Officer | Feb 26, 2026 | Buy | $1.58 | 20,571 | $32,479.55 | 628,813 | |
| Brooks Michael J | EDSA | President | Feb 26, 2026 | Buy | $1.57 | 2,000 | $3,140.00 | 226,870 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 13, 2026 · 99% conf.
Q4 2025 Earnings
8-K SELLFeb 13, 2026 · 99% conf.
1D
-5.58%
$0.96
Act: +0.49%
5D
-7.86%
$0.94
Act: -11.86%
20D
-8.15%
$0.94
Form 8-KFalse000154015900015401592026-02-132026-02-13iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2026
EDESA BIOTECH, INC.
(Exact name of registrant as specified in its charter)
British Columbia, Canada001-37619N/A (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.) 100 Spy Court Markham, Ontario L3R 5H6 (Address of Principal Executive Offices) (Zip Code) (289) 800-9600 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common SharesEDSAThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On February 13, 2026, Edesa Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended December 31, 2025 (the “Earnings Release”). The full text of the Earnings Release is attached hereto as Exhibit 99.1. The information furnished herein and therein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press release issued by Edesa Biotech, Inc. dated February 13, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EDESA BIOTECH, INC.
Date: February 13, 2026By: /s/ Peter J. Weiler Peter J. Weiler Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Dec 12, 2025
Q3 2025 Earnings
8-KDec 12, 2025
Form 8-KFalse000154015900015401592025-12-122025-12-12iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2025
EDESA BIOTECH, INC.
(Exact name of registrant as specified in its charter)
British Columbia, Canada001-37619N/A (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.) 100 Spy Court Markham, Ontario L3R 5H6 (Address of Principal Executive Offices) (Zip Code) (289) 800-9600 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common SharesEDSAThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On December 12, 2025, Edesa Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended September 30, 2025 (the “Earnings Release”). The full text of the Earnings Release is attached hereto as Exhibit 99.1. The information furnished herein and therein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press release issued by Edesa Biotech, Inc. dated December 12, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EDESA BIOTECH, INC.
Date: December 12, 2025By: /s/ Peter J. Weiler Peter J. Weiler Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 8, 2025
Q2 2025 Earnings
8-KAug 8, 2025
Form 8-KFalse000154015900015401592025-08-082025-08-08iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025
EDESA BIOTECH, INC.
(Exact name of registrant as specified in its charter)
British Columbia, Canada001-37619N/A (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.) 100 Spy Court Markham, Ontario L3R 5H6 (Address of Principal Executive Offices) (Zip Code) (289) 800-9600 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registered Common SharesEDSAThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On August 8, 2025, Edesa Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended June 30, 2025 (the “Earnings Release”). The full text of the Earnings Release is attached hereto as Exhibit 99.1. The information furnished herein and therein shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press release issued by Edesa Biotech, Inc. dated August 8, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EDESA BIOTECH, INC.
Date: August 8, 2025By: /s/ Peter J. Weiler Peter J. Weiler Chief Financial Officer
Compare EDSA vs Leading Stocks
See how EDSA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "EDSA Edesa Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.